Skip to Content
Contact Form Map & Directions Videos

Category: Defective Drugs

J&J Gets $1.2 Billion Pass on Risperdal Fine

03/27/2014
Defective Drugs
BY

Two years ago, healthcare giant Johnson & Johnson was facing a $1.2 billion judgment after a jury determined J&J concealed the risks of its antipsychotic drug Risperdal while it aggressively and improperly marketed it off-label. At the time it was the largest state fine over the mismarketing of Risperdal and […]

Read More

Living Off the Label

03/24/2014
Articles
BY

Doctors and physicians are given a great deal of discretion when it comes to prescribing drugs for uses other than those indicated by the FDA. This is known as “off-label” use. The FDA, realizing the danger of off-label promotion in its 2009 guidance, has set forth rules to restrict the […]

Read More

Drug Supplement Endangers Kids

03/19/2014
Articles
BY

It is a supplement used to treat children with a genetic disorder but instead has hospitalized at least one child. The Food and Drug Administration (FDA) reports lots of L-citrulline, sold by Medisca, had none of the active drug. The Plattsburgh, N.Y.-based compounding company was forced to recall eight lots […]

Read More

Compounding Problems

03/18/2014
Articles
BY

In the production of pharmaceutical drugs there are large scale drug manufacturers which produce brand name and generic drugs, and there are compound pharmacies which are specialty pharmacies made to fill out unique orders for clients using already existing medications. Drug manufacturers fall under FDA standards and regulations, while compounding […]

Read More

Proposed FDA Label Changes Irking Generic Drugmakers

03/10/2014
Articles
BY

Generic drugmakers are increasingly becoming more frightened of the threat of products liability lawsuits because of a proposed rule that would require them to change their labels if the company receives new safety information about the drug. These label changes would overturn a three decade old regime of prohibiting generic […]

Read More

Generic Drug Preemption

03/10/2014
Defective Drugs
BY

In 2009, the U.S. Supreme Court in Wyeth v. Levine held that brand-name drug manufacturers are responsible for their warning labels and may be liable for not adding additional warnings when new risks are discovered. However, in 2011, the Supreme Court held that failure-to-warn claims brought against generic drug makers […]

Read More

Study Suggests Paxil’s Link to Breast Cancer

03/4/2014
Defective Drugs
BY

Paxil (paroxetine) is a drug widely prescribed to treat depression. In women fighting breast cancer it is not uncommon to be prescribed Paxil. The newest research should cause health practitioners to give that practice a second thought. A team of California researchers developed a drug screening method which they applied […]

Read More

New Opioid Pain Pill to Hit the Market

03/3/2014
Articles
BY

Do we really need a new highly addictive opioid analgesic on the market to treat chronic pain, especially considering the high rates of drug addiction in the U.S? The drug Zohydro is set to be marketed come March and its approval is sparking a firestorm from consumer, drug addiction and […]

Read More

Hear What Our Clients Have To Say

"Every question that I had was answered in mere minutes and the follow through that the staff, secretaries and attorneys had was superior. I have dealt with many, many firms that have all disappointed me and Searcy Denney was by far the most thorough - I highly recommend them!"
Posted By: Susan Baker